Correlation of intravesical prostatic protrusion with severity of lower urinary symptoms among patients with benign prostatic hyperplasia

Babatunde K. Hamza1,2*, Muhammed Ahmed2, Ahmad Bello2,3, Musliu Adetola Tolani2,3, Mudi Awaisu2,3, Ahmad Tijjani Lawal2,3, Nasir Oyelowo2,3, Khalifah Ibrahim Abdulsalam2, Lateef Lawal2, Abdullahi Sudi3 and Hussein Yusuf Maitama2,3

Abstract

Background: Benign prostate hyperplasia (BPH) is characterized by an increase in the number of epithelial and stromal cells in the periurethral area of the prostate. Lower urinary tract symptoms (LUTS) often develop as a manifestation of bladder outlet obstruction (BOO) due to benign prostate enlargement. When the prostate enlarges, protrusion into the bladder often occurs as a result of morphological changes of the gland. Prostatic protrusion into the bladder can be measured with ultrasound as intravesical prostatic protrusion (IPP). There are studies that have shown IPP as a reliable predictor of bladder obstruction index (BOOI) as measured by pressure flow studies. IPP is thereby reliable in assessing the severity of BOO in patients with BPH. The severity of symptoms in patients with BPH can be assessed through several scoring systems. The most widely used symptoms scoring system is the International Prostate Symptomatics Score (IPSS). The aim of this study is to determine the correlation of IPP with IPSS in men with BPH at our facility.

Methods: The study was a cross-sectional observational study that was conducted at the Division of Urology, Department of Surgery, in our facility. The study was conducted on patients greater than 50 years LUTS and an enlarged prostate on digital rectal examination and/or ultrasound. All consenting patients were assessed with the International Prostate Symptoms Score (IPSS) questionnaire, following which an abdominal ultrasound was done to measure the intravesical prostatic protrusion (IPP), prostate volume (PV) and post-void residual (PVR) urine. All the patients had uroflowmetry, and the peak flow rate was determined. The data obtained were entered into a proforma. The results were analyzed using Statistical Package for Social Sciences (SPSS) software package version 20.

Results: A total of 167 patients were seen during the study period. The mean age was 63.7 ± 8.9 years, with a range of 45–90 years. The mean IPSS was 18.24 ± 6.93, with a range of 5–35. There were severe symptoms in 49.1%, while 43.1% had moderate symptoms and 7.8% had mild symptoms. The overall mean IPP was 10.3 ± 8 mm. Sixty-two patients (37.1%) had grade I IPP, 21 patients (12.6%) had grade II IPP and 84 patients (50.3%) had grade III IPP. The mean prostate volume and peak flow rate were 64 g ± 34.7 and 11.6 ml/s ± 5.4, respectively. The median PVR was 45 ml with a range of 0–400 ml. There was a significant positive correlation between the IPP and IPSS (P = 0.001). IPP also had a significant positive correlation with prostate volume and post-void residual and a significant negative correlation with the peak flow rate (P < 0.01).

*Correspondence: ridwankolapo@yahoo.com
1 Kaduna State University, Kaduna, Nigeria
Full list of author information is available at the end of the article

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
1 Background
Benign prostate hyperplasia is a condition intimately related to aging [1]. Histologically, it is a hyperplastic process that develops in the transition zone resulting from an increase in cell number. Microscopic evaluation reveals a nodular growth pattern that is composed of varying amounts of stroma and epithelium. Stroma is composed of varying amounts of collagen and smooth muscle [2]. The enlarged prostate can lead to bladder outlet obstruction which manifests clinically as LUTS. The size of the prostate is not a reliable predictor of the severity of LUTS [3, 4].

Pressure flow studies remain the gold standard to diagnose bladder outlet obstruction [5]. However, they are invasive, because catheterization is required to measure detrusor and urethral pressure, and they are uncomfortable for patients because of pain and voiding difficulty. Another important limitation of pressure flow study is the need for expensive equipments which are not readily available in many parts of the developing world. Thus, the need for a noninvasive, reliable and cost-effective alternative has led to suggestion of surrogates like intravesical prostatic protrusion (IPP). Ultrasonographic measurement of IPP is able to detect bladder outlet obstruction in patients with benign prostate hyperplasia quickly and noninvasively [6]. Intravesical prostatic protrusion is the distance in millimeters between the tip of the prostate median lobe and bladder neck in the midsagittal plane, using a suprapubically positioned ultrasound scanner.

The intravesical prostatic protrusion distance can be divided into three grades: grade I: 0–4.9 mm, grade II: 5–10 mm, and grade III: more than 10 mm [7].

Studies have shown that IPP is a reliable predictor of bladder outlet obstruction index (BOOI) as measured by pressure flow studies [8, 9].

The severity of lower urinary tract symptoms can be measured reliably with a number of validated questionnaires like International Prostate Symptoms Score (IPSS), Boyarsky score, Madsen score, Iversen score and Danish prostatic symptom score. The IPSS is recommended as the symptom scoring instrument to be used for the baseline assessment of symptom severity in men presenting with lower urinary tract symptom [10].

The present study will aim to determine the correlation between intravesical prostatic protrusion (IPP) and International Prostate Symptoms Score (IPSS).

2 Methods
The study was conducted at the Division of Urology, Department of Surgery, in our center, between September 2015 and August 2016. Approval was obtained from the health research ethics committee (HREC) prior to the commencement of the study. A written informed consent was obtained from all participants. All adult males greater than 50 years, presenting with LUTS and an enlarged prostate on DRE or ultrasound, were included in the study. Patients on medical therapy for BPH, BPH coexisting with urethral stricture, suspected prostate cancer and those with neurogenic bladder were excluded.

All enrolled patients were evaluated at the time of initial visit using the IPSS questionnaire. A digital rectal examination was done on each patient to assess the prostate size and characteristics. Uroflowmetry was done using ARK Meditech System Uroflowmetry Machine: Urol 010 Model. The abdominal ultrasound was done using a Mindray Digital Ultrasonic Diagnostic Imaging System: Model DP-20 with an abdominal probe frequency of 3.5 MHz by the same radiologist in the radiology department. IPP was measured when the bladder contained about 100–200 ml of urine. This was measured as the distance in millimeters between the tip of the prostate median lobe and bladder neck in the midsagittal plane and divided into three grades (grade I: 0 – 4.9 mm; grade II: 5.0–10.0 mm; and grade III: greater than10.0 mm). The prostate volume and post-void residual urine were also determined.

The data obtained were recorded in a proforma and entered into statistical software. Statistical Package for Social Sciences (SPSS) software version 20 was used for data analysis. The correlation between IPP and IPSS was determined using Spearman correlation coefficient. The correlation between IPP and the surrogates of BOO (prostate volume, Qmax and PVR) was also determined using Spearman correlation coefficient. The correlation between the surrogates of BOO and IPSS was determined using Pearson's correlation coefficient. Statistical significance (P) value was set at 0.05. Statistical significance (P) value was set at 0.05.

3 Results
A total of 167 patients met the inclusion criteria. The mean age was 63.7±8.9 years, with a range of 45–90 years. The peak age group was 60–69 years as
shown in Table 1. Majority (50.3%) had grade III IPP as shown in Table 2.

The mean IPSS was 18.24 ± 6.93, with a range of 5–35. Eighty-two patients (49.1%) had severe symptoms; others are shown in Fig. 1.

The quality of life assessments showed that majority of the patients were unhappy with their symptoms (47.9%) as shown in Fig. 2.

Eighty-two patients (49.1%) had severe symptoms of which 23 patients (12.8%), nine patients (5.45%) and 50 patients (29.9%) had grade I, grade II and grade III IPP, respectively. Seventy-two patients (43.1%) had moderate symptoms of which 28 patients (16.8%), 12 patients (7.2%) and 32 (19.2%) patients had grade I, grade II and grade III IPP, respectively. Thirteen patients (7.8%) had mild symptoms of which 11 patients (6.6%) and two patients (1.2%) had grade I and grade III IPP, respectively.

The mean IPP was 10.2 ± 8 mm, with a range of 0–28.2 mm. See Table 3 for the distribution of individual IPP category.

There was a positive correlation between the IPP versus IPSS storage, IPSS voiding, IPSS (total) and quality of life scores. The correlations were weak but statistically significant (Table 4).

The mean prostate volume was 64 g ± 34.7, with a range of 18.6–176.8 g. Most (117 patients) had prostate volumes ≥ 40 g, of which 21.6%, 10.2%, and 38.3% had grades I, II and III IPP, respectively (Table 5).

The mean Q max was 11.6 ml/s ± 5.4 with a range of 2–21 ml/s. Seventy-seven (46.1%) patients had flow < 10 ml/s of which 12%, 5.4%, and 28.7% had grades

| Table 1 Age distribution of 167 men with BOO secondary to BPH |
|-------------------|---------------|-----------|
| Age (years)       | Frequency     | Percentage|
| 40–49             | 12            | 7.1       |
| 50–59             | 36            | 21.6      |
| 60–69             | 73            | 43.7      |
| 70–79             | 40            | 24.0      |
| 80–89             | 4             | 2.4       |
| 90–99             | 2             | 1.2       |
| Total             | 167           | 100       |

| Table 2 Distribution of the study population according to IPP grading |
|-------------------------|----------|----------|
| IPP grading             | Frequency| Percentage|
| Grade I (< 5 mm)        | 62       | 37.1     |
| Grade II (5–10 mm)      | 21       | 12.6     |
| Grade III (> 10 mm)     | 84       | 50.3     |
| Total                   | 167      | 100      |

| Table 3 Demographics and clinical characteristics of individual IPP category |
|--------------------------|----------|----------|----------|----------|
|                         | Grade I  | Grade II | Grade III| Total     |
| Mean age (years)        | 61.65 ± 7.5 | 65 ± 9.3 | 65 ± 9.6 | 63.7 ± 8.9 |
| Mean IPP (mm)           | 2.1 ± 1.9   | 7.8 ± 1.0 | 18.7 ± 4.4 | 10.2 ± 8.0 |
| Mean IPSS (total)       | 16.23 ± 6.9 | 17.1 ± 6.7 | 20 ± 6.6 | 18.24 ± 6.93 |
| Mean IPSS (storage)     | 7.61 ± 3.6  | 8.86 ± 2.7 | 9.5 ± 3.2 | 8.7 ± 3.3  |
| Mean IPSS (voiding)     | 8.48 ± 4.2  | 8.29 ± 4.8 | 10.5 ± 4.9 | 9.4 ± 4.7  |
| Mean QoL                | 4.06 ± 1.2  | 4.19 ± 1.4 | 4.48 ± 1.2 | 4.3 ± 1.3  |
| Mean PV (g)             | 46.9 ± 21.4 | 64.1 ± 41.3 | 72.2 ± 37.2 | 64 ± 34.7  |
| Mean Qmax (ml/s)        | 13.4 ± 5.2  | 13.8 ± 6.0 | 9.7 ± 4.8 | 11.6 ± 5.4  |
| Median PVR (ml)         | 18         | 13.8      | 100       | 45        |

Fig. 1 A pie chart showing the frequency of severity of symptoms based on IPSS

Fig. 2 A bar chart showing the quality of life assessment of the patients (n = 167)
I, II, and III IPP, respectively. Most of the patients with grade III IPP had Q max < 10 ml/s (Table 5).

The median PVR was 45 ml with a range of 0–400 ml. Only 14.4% had PVR ≥ 200 ml, most of them with grade III IPP.

Intravesical prostatic protrusion had positive correlation with prostate volume and post-void residual.

Intravesical prostatic protrusion also had a negative correlation with the Q max. The correlations were all statistically significant (Table 5).

There was a positive correlation between the IPSS (voiding, storage and total) and post-void residual urine; this was found to be statistically significant. There was negative correlation between the IPSS (voiding, storage and total) and Qmax. This was also found to be statistically significant (Table 6).

However, there was no correlation between the prostate volume and the IPSS (voiding, storage and total) (Table 6).

4 Discussion
A total of 167 patients were evaluated for BOO secondary to BPH during the study period. The mean age was 63.7 years ± 8.9 years, with a range of 45–90 years. The mean age is similar to the findings of Udeh et al. [11] in north central Nigeria who reported a mean age of 65.6 ± 9.84 years, and Badmus et al. [12] in south western

| Variable      | IPP, number (%) | Correlation with IPP | P value |
|---------------|-----------------|----------------------|---------|
| Prostate volume |                 |                      |         |
| < 40 g        | 26(15.6%)       | 40–100 g             | 50(29.9%)                       |
| > 100 g       | 0               | 40(24%)              | 0.422 0.000                     |
| Q max         |                 |                      |         |
| < 10 ml/s     | 20(12%)         | 10–15 ml/s           | 48(28.7%)                       |
| > 15 ml/s     | 28(16.7%)       | 10(6.0%)             | 50(29.9%)                       |
| PVR           |                 |                      |         |
| < 50 ml       | 40(24%)         | 13(7.8%)             | 26(15.6%)                       |
| 50–199 ml     | 14(8.4%)        | 6(3.6%)              | 40(24%)                         |
| ≥ 200 ml      | 4(2.4%)         | 2(1.2%)              | 18(10.8%)                       |

Correlation is significant at the 0.01 level
r_s*: Spearman's correlation coefficient

| Variable      | IPSS, P value  | Q max, P value | Post-void residual urine, P value |
|---------------|---------------|----------------|-----------------------------------|
| IPSS (storage)| 0.057         | −0.181         | 0.225                             |
| IPSS (voiding)| 0.019         | 0.019          | 0.04                              |
| IPSS (total)  | 0.019         | 0.001          | 0.001                             |
| QoL           | 0.119         | 0.012          | 0.00                              |

P < 0.05 is significant
Nigeria who reported a mean age of 64.4 ± 8.88 years. Similar findings have also been reported by other studies [13, 14]. Most of the patients in this study presented in the seventh decade. The peak age of presentation is similar to the findings of Udheh and Movsav et al. [11, 15].

The mean IPSS was 18.24 ± 6.93, which was within moderate score on IPSS. Severe symptoms on IPSS were found in 49.1%, while 43.1% had moderate symptoms and 7.8% had mild symptoms. There are studies (in patients with BPH ± IPP) that have reported the mean IPSS both in the moderate [14, 16] and severe range [17, 18]. The preponderance of severe symptoms can be partly explained by that the Urology clinic in our hospital is a referral center; patients are more likely to be referred to the Urologists if their symptoms are bothersome (moderate to severe score on IPSS). A population-based study is likely have more patients with mild symptoms compared to hospital-based studies. Ezeanyika et al. [19] in a population-based study in Nsukka, Nigeria, on males without apparent symptoms of ill health reported 74.65% as having mild symptoms on IPSS, while 23.58% and 1.77% had moderate and severe symptoms, respectively. Another possible explanation as to why most patients present with moderate to severe symptoms is that many men often attribute the changes in urinary pattern to inevitable consequence of aging, they eventually present to the Urologist when the symptoms become bothersome as noted by Oranusi et al. [20].

The QoL score showed that most patients were unhappy with their symptoms (46.1%). There was also a strong positive correlation between the IPSS and QoL. This is similar to the findings of Adegun et al. [21]. They further suggested that the QoL should serve as the basis of treatment rather than the IPSS.

The mean IPP in this study was 10.3 mm which was within grade III IPP. This is similar to the findings of Agbo [22] and Sidgel et al. [23] who reported mean IPP of 12.9 mm and 14.6 mm, respectively. About half of the patients (50.3%) had grade III IPP. This is comparable with the findings of Reis et al. [13] and Eze et al. [24] in which grade III IPP constituted 59.5% and 59.4% of their study populations, respectively. However, there are other studies with preponderance of IPP grade I and grade II. [25, 26] Kuei et al. [26] in a study of Asian population reported 66.1%, 18.8% and 15.2% for grade I, grade II and grade III, respectively. The mean prostate volume in that study was 40 ml. The geographical location and smaller mean prostate volume may explain why there was preponderance of grade I IPP.

In this study, there was a significant positive correlation between the IPP and IPSS, IPSS sub scores and QoL. This finding is supported by several studies that have reported a significant positive correlation between the IPP and IPSS [22, 24, 27, 28]. However, there are other studies that did not reveal any correlation between IPP and IPSS [23, 29]. This can be attributed to a number of factors. It has been noted that different bladder volumes affect the degree of protrusion of the prostate into the bladder, which eventually affect the grading of IPP [30]. Too little urine allows more protrusion of the prostate into the bladder, while a full bladder will reduce the protrusion of the prostate into the bladder. Yuen et al. [30] in a study to determine the effect bladder volume on prostatic protrusion concluded that IPP should be measured between 100 and 200 ml. Sidgel et al. [23] used a different bladder volume to measure the IPP (150–250 ml), while Hou et al. [29] did not mention the bladder volume at which IPP was measured. Measurement of IPP is also operator dependent, Hou et al. [29] was not explicit whether they used a single radiologist or otherwise.

There are several studies that shown IPP as a reliable predictor of BOOI as measured by pressure flow studies [8, 9]. Chia et al. [8] considered IPP to be a useful parameter to predict BOO because of its good correlation with conventional pressure flow studies. Chia et al. [8] also found that 75% of men with significant BOO had IPP greater than 10 mm, whereas only 8% of men with no significant BOO had IPP greater than 10 mm. Keqin Z et al. [9] found that IPP was positively correlated with bladder outlet obstruction index. IPP greater than 10 mm appeared more often in the obstructed patients.

This study revealed a significant positive correlation between IPP and other parameters of BOO (PV, Qmax and PVR).

Lee et al. [28] in a prospective study of 114 men with BOO secondary to BPH, found a positive correlation between IPP and prostate volume. Both IPP and PV had a significant positive correlation with BOOI; however, IPP had a better correlation with BOOI than prostate volume. Han et al. [31] also reported significant positive correlation between IPP with prostate volume (r = 0.534, P < 0.01). Gyawali et al. [32] had a different outcome, in a prospective study of 60 men with LUTS; found that IPP had no correlation with PV. This study however had a smaller sample size.

The mean Qmax in this study was 11.6 ml/s. Most men with grade III IPP had flow < 10 ml/s. There was a significant negative correlation between the IPP and Qmax. Similarly Han et al. found out that the degree of IPP is negatively correlated with the Qmax (−0.364, P < 0.01) [31]. Liber et al. [33] in a sample of 322 men residing in Olmsted county, reported significant correlation between IPP and higher obstructive symptoms and Qmax (r = −0.18, P < 0.01). However, Sidgel et al. [23] in a prospective study of 50 patients with BPH reported IPP had a positive correlation with Qmax, but it was not
In this study, IPP had a significant positive correlation with PVR urine. This has also been reported from other studies [28, 29].

In this study, both the Qmax and PVR urine had a significant correlation with the IPSS. Barry MJ and Girman CJ [34], Bosch et al. [35] and Din et al. [36] have reported weak but significant correlations between Qmax and symptom scores, while Singla et al. [37] and Kolman C et al. [38] both reported significant positive correlation between PVR urine and IPSS.

In this study, there was no correlation between prostate volume and IPSS. There are studies that have reported similar findings [39, 40]. Symptoms severity is determined by other factors and not necessarily the size of the prostate alone.

Apart from predicting symptoms severity, IPP can also be useful predictor for successful trial without catheter (TWOC). A TWOC is more likely to fail in patients with IPP larger than 10 mm [41]. Patients with grade III IPP can be identified earlier as such patients are more likely to require surgical intervention [42].

5 Conclusion

Intravesical prostatic protrusion is a reliable predictor of severity of LUTS as measured by IPSS. Patients with grade III IPP are likely to present with severe symptoms. IPP also shows good correlation with other surrogates of BOO (prostate volume, Qmax and post-void residual urine).

Abbreviations

BPE: Benign prostatic enlargement; BPH: Benign prostate hyperplasia; BOO: Bladder outlet obstruction; DRE: Digital rectal examination; IPSS: International Prostate Symptoms Score; QoL: Quality of life; IPP: Intravesical prostatic protrusion; PV: Prostate volume; PVR: Post-void residual; LUTS: Lower urinary tract symptoms; Qmax: Peak flow rate; SPSS: Statistical package for the social sciences; PFR: Peak flow rate.

Acknowledgements

Not applicable.

Authors' contributions

B.K.H. contributed to project development, manuscript writing, data collection, data analysis and editing. M.A (Ahmed), A. B and H.Y.M helped with project development and editing. M.A.T contributed to data collection, data analysis, and editing. M.A (Awaisu), AT, L, N.O, K.I.A, L. L and A. S helped with data collection and editing. All authors have read and approved the manuscript.

Funding

None.

Availability of data and materials

Raw data are available at the request of the author.

Ethical approval and consent to participate

This study was approved by the health research ethics committee (HREC) of Ahmadu Bello University Teaching Hospital Zaria (Reference number: ABUTHZ/HREC/N09/2015). A written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

None.

Author details

1 Kaduna State University, Kaduna, Nigeria. 2 Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. 3 Ahmadu Bello University Zaria, Zaria, Nigeria.

Received: 23 April 2020 Accepted: 14 December 2020

Published online: 07 January 2021

References

1. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ et al (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150:85–89
2. Presti JC Jr, Christopher J, Kane M, Kausto Shinohara M, Peter R, Carroll M (2008). Neoplasms of the prostate gland. In: Smith’s general urology, 17th edn. McGraw-Hill, p 349.
3. Agrawal CS, Chalise PR, Bhandari BB (2008) Correlation of prostate volume with international prostate symptom score and quality of life in men with benign prostatic hyperplasia. Nepal Med Coll J 10:104–107
4. Ofoha CG, Shu SI, Akpayak IC, Dakum NK, Ramyil VM (2013) Relationship between Prostate volume and IPSS in African men with Prostatic disease. JOS J Med 9:16–19
5. Nitti VW (2005) Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol 7:14–21
6. Hossein AKMS, Alan AKMK, Habib AKMK, Rashid MM, Rahman H et al (2012) Comparison between prostate volume and intravesical prostatic protrusion in detecting bladder outlet obstruction due to benign prostatic hyperplasia. Bangladesh Med Res Counc Bull 38(1):14–17
7. Bachmann A, Descazesaud A, Emberton M, Gravas S, Michel MC, Nordling J (2012). Guidelines on male lower urinary tract symptoms (LUTS ), including Benign Prostatic Obstruction (BPO). Eur Assoc Urol 123–144.
8. Chia SJ, Heng CT, Chan SP, Foo KT (2003) Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int 91:371–374
9. Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S (2007) Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. Urology: 70:1096–10999
10. McNicholas TA, Kirby RS, Lepor H (2012) Evaluation and Nonsurgical management of Benign Prostate Hyperplasia. In: Campbell-walsh urology, 10th edn. Elsevier, pp 2615–2616
11. Udeh E, Ozoemenia OF, Ogwuche E (2013) The relationship between prostate volume and international prostate symptom scores in Africans with benign prostatic hyperplasia. Niger J Med 21:120–125
12. Badmus TA, Asaley CM, Badmus SA, Takure AO, Ibrahim MH, Arowolo OA (2012) Benign prostate hyperplasia - average volume in southwestern Nigerians and correlation with anthropometrics. Niger Postgrad Med J 19:15–18
13. Reis LO, Barreiro GC, Baracat J, Prudente A, D’Ancona CA (2008) Intravesical protrusion of the prostate as a predictive method of bladder outlet obstruction. Int Braz J Urol 34:627–633
14. Mohammed AZ, Alhassan SU, Edino ST, Ochicha O (2003) Histopathological review of prostatic diseases in Kano. Nigeria Niger Postgrad Med J 101:1–5
15. Movsas S (1966) Prostatic obstruction in the African and Asiatic. Br J Surg 53:538–543
16. Hou CP, Lin YH, Chen CL, Tsai YL, Chang PL, Tsui KH (2016) Impact of the static prostatic urethral angle on men with lower urinary tract symptoms. Urol Sci 27:47–50
